Top European Growth Companies With High Insider Ownership August 2026
As European markets experience a boost from resilient earnings and increased risk appetite, investors are keenly observing growth companies with high insider ownership. In this environment, stocks with strong insider commitment can offer insights into potential long-term value, aligning well with the current market's focus on stability amidst geopolitical volatility.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 61.1% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 73.9% |
| CD Projekt (WSE:CDR) | 35.2% | 39% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.8% |
| BioArctic (OM:BIOA B) | 32.2% | 62.3% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
We'll examine a selection from our screener results.
Canatu Oyj (HLSE:CANATU)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Canatu Oyj specializes in the development and sale of carbon nanotubes and related products, along with manufacturing equipment for industries such as semiconductor, automotive, and medical diagnostics across Finland, the United States, Japan, and Taiwan; it has a market cap of €235.07 million.
Operations: The company's revenue from Semiconductor Equipment and Services is €16.70 million.
Insider Ownership: 12.6%
Canatu Oyj is positioned for significant growth, with revenue expected to rise by 31.5% annually, surpassing both market and industry benchmarks. Despite its volatile share price, the stock trades at 60.2% below estimated fair value, suggesting potential upside as analysts anticipate a 42.4% price increase. Recent leadership changes include appointing Dr. Maximilian Slawinski as CEO and Walter Braun as CTO, bringing extensive experience in scaling operations and driving growth initiatives globally.
- Get an in-depth perspective on Canatu Oyj's performance by reading our analyst estimates report here.
- Our valuation report unveils the possibility Canatu Oyj's shares may be trading at a discount.
Egetis Therapeutics (OM:EGTX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Egetis Therapeutics AB (publ) is a pharmaceutical company focused on the development and commercialization of orphan drugs in Sweden and internationally, with a market cap of SEK3.25 billion.
Operations: The company's revenue primarily comes from its Emcitate segment, which generated SEK63.10 million.
Insider Ownership: 18.4%
Egetis Therapeutics is poised for robust growth, with revenue projected to increase by 36.9% annually, outpacing the Swedish market. The stock trades at 89.6% below its estimated fair value, indicating potential upside. Despite past shareholder dilution and low forecasted return on equity of 3%, Egetis is expected to become profitable within three years, surpassing average market growth rates. Recent participation in international conferences highlights its strategic focus on expansion and visibility.
- Dive into the specifics of Egetis Therapeutics here with our thorough growth forecast report.
- Our valuation report here indicates Egetis Therapeutics may be overvalued.
Leonteq (SWX:LEON)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Leonteq AG is a company that offers derivative investment products and services across Switzerland, Europe, Asia, and internationally with a market cap of CHF305.13 million.
Operations: Leonteq generates revenue primarily from its brokerage segment, which amounts to CHF157.98 million.
Insider Ownership: 12.3%
Leonteq is positioned for growth, with earnings forecasted to increase by 50.22% annually and revenue expected to grow at 15.8% per year, surpassing the Swiss market average. Trading at a good value compared to peers, Leonteq recently reported a net income of CHF 12.69 million for the first half of 2026, up from CHF 9.26 million last year. The conclusion of regulatory proceedings provides clarity for its strategic priorities moving forward.
- Click here to discover the nuances of Leonteq with our detailed analytical future growth report.
- Insights from our recent valuation report point to the potential undervaluation of Leonteq shares in the market.
Key Takeaways
- Explore the 220 names from our Fast Growing European Companies With High Insider Ownership screener here.
- Searching for a Fresh Perspective? Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com